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Abstract
Background: Deletions of the α-globin genes are the most common genetic abnormalities in the world. Currently
multiplex Gap-PCRs are frequently used to identify specific sets of common deletions. However, these assays
require significant post-amplification hands on time and cannot be used to identify novel or unexpected deletions.
The aim of the current study was to develop a rapid screening test for the detection of all deletions of the α-globin
genes that can be integrated into a high volume clinical laboratory workflow.
Methods: A gene ratio assay copy enumeration (GRACE) PCR method was developed by simultaneous
amplification of targets in the α-globin genes (HBA1 and HBA2) and the chloride channel voltage sensitive 7
(CLCN7) reference gene. A novel application of High Resolution Melting (HRM) analysis then allowed rapid
determination of α-globin gene copy numbers. The assay was validated using 105 samples with previously
determined and 62 samples with unknown α-globin genotypes.
Results: The GRACE-PCR assay detected abnormal α-globin gene copy numbers in 108 of the 167 samples
evaluated. The results were consistent with those from a commercial reverse hybridization assay and no allele drop
out was observed.
Conclusions: We have successfully developed and validated a GRACE-PCR screening test for the detection of
deletions and duplications of the α-globin genes. The assay is based on copy number determination and has the
ability to detect both known and novel deletions of the α-globin genes. It is a closed tube technique; consequently
the risk of amplicon contamination is negligible. Amplification, detection and analysis can be completed within one
hour, making it faster, cheaper and simpler than other existing tests and thus well suited as a rapid first step in a
clinical laboratory workflow.
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Background
Deletions of the α-globin genes are the most common
genetic disorders in the world. The World Health
Organization (WHO) estimates that 20 % of the world’s
population may have a deletion in one or more α-globin
genes [1]. The majority of these cases are asymptomatic
carriers, where the deletion of one or two α-globin genes
may provide some protection against malaria [1, 2].
However, deletion of three genes causes a form of thalas-
saemia intermedia known as Hb H disease and often re-
sults in significant anaemia. Deletion of all four α-globin
genes leads to Hb Barts hydrops foetalis syndrome and
normally results in foetal death; such pregnancies are
also associated with a significant risk of maternal mor-
bidity or mortality [3]. It has been estimated that around
13,000 pregnancies are affected annually by severe forms
of α-thalassaemia [1].
Normal haemoglobin is a tetramer composed of two
α-globin and two β-globin chains. There are two func-
tional α-globin genes, designated Haemoglobin Alpha 1
(HBA1) and Haemoglobin Alpha 2 (HBA2). These genes
are 97 % homologous and are located 2941 bp apart on
chromosome 16 in a region known as the α-globin locus
(Fig. 1) [4]. In contrast to β-thalassaemia, where deletions
are relatively rare, the majority of α-thalassaemia cases
arise from gene deletions [2]. The designation α+ is used
to describe a chromosome with reduced α-globin gene
expression, while αo describes a chromosome with no
gene expression [4]. Typically, α+ thalassaemia alleles re-
sult from a small deletion that leaves just one functional
α-globin gene on the chromosome, although there are
also non-deletional forms that arise as the result of a
point mutation. αo Thalassaemia alleles are normally
caused by larger deletions affecting both the HBA1 and
HBA2 genes [2].
Identification of α-globin gene deletions is often per-
formed in a clinical laboratory setting using either Gap-
PCR or reverse hybridization. A number of multiplexed
assays based on these techniques have been described
for the most common deletions [5–9]. These techniques
are simple and fairly robust, but the use of either agarose
gel electrophoresis or hybridization for identification
makes them relatively time consuming and labour inten-
sive. Thus, these technologies are not particularly con-
venient for high throughput testing in a routine clinical
laboratory. An additional limitation of these techniques
is that they only identify specific targeted deletions and
rare or novel deletions may be missed.
Due to these limitations, methods for the detection α-
globin gene deletions based on a number of alternative
Fig. 1 A schematic representation of the α-globin locus from the Haemoglobin Zeta (HBZ) to the Haemoglobin Theta 1 (HBQ1) gene. The
approximate position of the gene deletions detected in the current study is shown. The location of amplicons targeting the HBA1 and HBA2
genes are indicated by the arrows A1 and A2, respectively. The CLCN7 gene is located approximately 1.3 million bases 3′ of the α-globin locus
(not shown)
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techniques have been developed. These include Multi-
plex Ligation-dependent Probe Amplification (MLPA)
[10, 11], Denaturing High Performance Liquid Chroma-
tography (DHPLC) [12, 13], Quantitative PCR (qPCR)
[14–18] and melting curve analysis [19–21]. Melting
curve analysis methods are particularly attractive, since
they do not require post amplification processing by
electrophoresis or chromatography. A novel technique
based on co-amplification of a target and a reference
gene, followed by melting analysis has been described
for the Adenomatous Polyposis Coli (APC) gene [22].
More recently this technique has also been applied to
the Ataxia telangiectasia mutated serine/threonine kin-
ase (ATM) and the Phosphate and tensin homolog
(PTEN) genes [23]. Here we describe the use of a similar
approach to develop a novel gene ratio assay copy enu-
meration (GRACE) screening test for the simultaneous
copy number determination of the HBA1 and HBA2
genes relative to the reference gene chloride channel
voltage sensitive 7 (CLCN7) [14]. This GRACE-PCR
screening test is a single tube assay that can detect any
rearrangements of the α-globin genes that affect the 3′
ends of the HBA1 or HBA2 genes. In contrast to most
previously described assays for deletion or duplication of
the α-globin genes, the GRACE-PCR assay is a simple
closed tube technique, which requires no further hands
on time after the initial PCR setup. Data analysis is per-
formed by a novel application of the standard features of
the HRM analysis software, making it high throughput
and well suited for performing rapid initial screening of
samples in the clinical laboratory.
Methods
Samples
This study was conducted using anonymous, archived
material from blood specimens submitted to the Sheikh
Khalifa Medical City (SKMC) laboratory, Abu Dhabi,
United Arab Emirates for α-thalassaemia screening. Eth-
ical clearance was obtained from the SKMC Institutional
Research and Ethics Committee to use this material for
the current study. In total 167 samples were used.
The performance characteristics of the GRACE-PCR
assay were originally established using 105 samples with
known genotype. These samples were selected to repre-
sent as many different α-globin genotypes as possible.
Samples with point mutations of the HBA2 gene in the
stop codon or untranscribed region (UTR) were also in-
cluded to assess their impact on assay performance. The
assay was further validated using an additional 62 sam-
ples of unknown genotype.
DNA Extraction
Genomic DNA was extracted from whole blood using
the QIAamp DNA Blood Mini kit (Qiagen, Germany) in
accordance with the Manufacturer’s instructions. The
concentration of the extracted DNA was measured using
a NanoDrop 2000 spectrophotometer (Thermo Scien-
tific, USA) and adjusted to 10 ng/μl with 10 mM Tris,
0.5 mM EDTA (pH 9.0).
Genotyping
All samples included in the study were genotyped using
the CE-IVD (Conformité Européene - In Vitro Diagnos-
tics) marked α-Globin StripAssay (ViennaLab Diagnos-
tics, Austria) in accordance with the manufacturer’s
instructions. The StripAssay is able to detect the αααanti3.7
duplication and the following deletions: -α3.7, -α4.2, -(α)20.5,
–SEA, –Med, –Fil, –Thai in addition to a number of point
mutations including αConstant Springα, αIcariaα, αpolyA-1α and
αpolyA-2α.
Primer design and synthesis
To detect deletions in HBA1 and HBA2 simultaneously
three primer pairs targeting the HBA1, HBA2 and
CLCN7 genes were used in the GRACE-PCR assay
(Table 1). All primers were designed using Oligo Primer
Analysis Software version 7.56 (Molecular Insights,
USA). The approximate location of the amplification
sites for the HBA1 and HBA2 genes along with the
locations of the deletions identified in the current
study are shown in Fig. 1. Primers were specifically
designed to work at the same annealing temperatures,
but to generate products with melting temperatures
approximately 3 °C apart. Alternative primer pairs
were also developed to amplify HBA2 and CLCN7
genes by GRACE-PCR to investigate anomalous re-
sults from the original GRACE-PCR (Additional file 1:
Table S1).
High Performance Liquid Chromatograph (HPLC)
purified primers were commercially synthesized (Meta-
bion, Germany).
GRACE-PCR and data analysis
Each 12.5 μL GRACE-PCR reaction contained 20 ng of
genomic DNA, 0.25 units of Kappa HiFi HotStart poly-
merase (Kappa Biosystems, Boston, USA), 0.25 units of
Platinum Taq polymerase (Invitrogen, Carlsbad, USA),
0.5 μL of LightCycler 480 ResoLight dye (Roche Diag-
nostics, Mannheim, Germany), 1x Kappa GC buffer
(Kappa Biosystems), 0.3 mM of each dNTP (Kappa Bio-
systems), 0.45 μM of each primer for the HBA1 and
HBA2 genes and 0.16 μM of each primer for the CLCN7
gene.
PCR was performed using a Rotor-Gene Q-5plex
HRM thermocycler (Qiagen, Germany). This system can
accommodate up to 72 PCR reactions per run. After an
initial 5 min hold at 95 °C, 27 cycles of PCR were per-
formed as follows: 10 s at 98 °C, 10 s at 58 °C and 10 s
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at 72 °C. Melting was performed at a rate of 0.2 °C/s
over the temperature range 77 °C to 87 °C, with data ac-
quisition on the HRM channel. PCR conditions for the
alternative primers are given in the Additional file 1:
Method section.
Data analysis was performed using the HRM module
Rotor-Gene Q series software version 1.7.
Results
GRACE-PCR design and optimisation
Initially, we used Platinum Taq polymerase in combin-
ation with 1.2 M betaine during the development of the
GRACE-PCR assay. This strongly favoured the amplifica-
tion of HBA2 over HBA1, which made the quantification
of the latter difficult. This issue could not be resolved by a
Table 1 Primers used for the GRACE-PCR alpha globin copy number assay








Position on Ref Sequence
NC_000016.10
Forward CACCCGGCCTCATGGAT CLCN7 0.16 155 79.4 1,462,101 to 1,462,255
Reverse AAGAGAACTACAGACCAACACCC
Forward CCATCTTTACGTTTCTGGGCACTC HBA1 0.45 131 82.2 177,800 to 177,930
Reverse GCCATGCTGGAGTGGGACTTC
Forward CCGTTAAGCTGGAGCCTCGGT*A HBA2 0.45 171 85.2 173,594 to 173,764
Reverse ACACCTCCATTGTTGGCACAT
*indicates the use of phosphorothioate (PTO) to block 3′ exonuclease activity
Fig. 2 GRACE-PCR assay, limited cycle multiplex PCR targeting both α-globin genes (HBA1 and HBA2) and a reference gene (CNCN7). Peak height,
relative to the reference gene, in the melting plots (−dF/dT versus temperature) is proportional to the copy number of each gene (indicated in
parenthesis under the gene name). Four genotypes with varying α-globin gene copy numbers are shown in plots a to d
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simple redesign of the primers. Consequently, various al-
ternative enzymes and enhancers were tried and with the
use of an enzyme cocktail containing Platinum Taq and
Kappa HiFi HotStart polymerases simultaneous and com-
parable amplification of HBA1 and HBA2 was achieved
(Fig. 2). The Kappa HiFi HotStart polymerase has 3′ to 5′
exonuclease proofreading activity, thus to avoid misprim-
ing of the HBA2 forward primer to HBA1 a phosphoro-
thioate (PTO) block was incorporated in the primer
sequence (Table 1) [24]. Amplification of the CLCN7 con-
trol gene [14, 25] was more efficient than that of the target
α-globin genes, which was corrected by reducing the con-
centration of the CLCN7 primers (Table 1). Limiting the
number of PCR cycles resulted in termination of amplifi-
cation during the exponential phase of the PCR reaction.
This ensured that the relative amount of each PCR prod-
uct remained proportional to the initial number of copies
of the gene present.
Data analysis
The amount of PCR product from each of the three
genes targeted in the GRACE-PCR assay is proportional
to the height of the peak on the -dF/dT versus
temperature plots (Fig. 2). Initially we determined the
gene copy numbers by measuring peak heights on the
-dF/dT plots (Fig. 2) and then normalized the data to a
wild type control sample included in the same run using
the following calculation: Normalized ratio = (RWT Con-
trol/TWT Control)/(RUnknown/TUnknown); where R and T are
the peak heights for the reference (CLCN7) and the tar-
get (HBA1 or HBA2) genes, respectively. The subscript
‘WT Control’ indicates the wild type control sample.
This process worked well and allowed the correct copy
number for both α-globin genes to be determined for all
samples tested (Fig. 3). However, this method of data
analysis was complex and time consuming. Conse-
quently, we developed a simplified visual method for
data analysis, which utilized features available in the
HRM module Rotor-Gene Q series software (Fig. 4) and
eliminated the need for manual calculations.
As expected in the GRACE-PCR assay three distinct
melt transition steps could be observed in the melting
curves corresponding to the melting temperatures of the
PCR products initially designed to be 3°C apart (Fig. 4a,
Table 1). Therefore, the steps could be assigned to the
melting of the products from CLCN7, HBA1 and HBA2
genes as indicated in Fig. 4a. Normalization of the raw
HRM data was performed in two stages using the Rotor-
Gene Q series software. First the data was normalized by
setting normalization ranges before the melting of the
CLCN7 product and after the melting of the HBA1 prod-
uct (normalization ranges N1 and N2 indicated by the
dark grey bars in Fig. 4). This resulted in a plot in which
the height of the curve between the CLCN7 and HBA1
melt regions is dependent on the gene copy number ra-
tio of CLCN7:HBA1. Inclusion of a known wild type
control sample in each run allowed rapid visual deter-
mination of any samples with abnormal copy numbers
for HBA1 (Fig. 4b). Since the number of copies of the
CLCN7 reference gene is assumed to be two, this ratio
can be used to determine the copy number for the
HBA1 gene. In the second stage of the analysis
normalization ranges were set before the melting of the
HBA1 product and after the melting of the HBA2 prod-
uct (using the normalization ranges N3 and N4 indi-
cated by the light grey bars in Fig. 4c). This resulted in a
plot allowing the gene copy number ratio of
HBA1:HBA2 to be determined (Fig. 4c). Since the copy
number for the HBA1 gene was already determined in
the first stage of the analysis this ratio allowed the copy
number for HBA2 to be easily derived. This alternative
visual method of analysis led to identical results as the
more complex calculation method for all 167 samples
included in the study, but proved far quicker and sim-
pler to perform.
Assessment and validation of the GRACE-PCR assay
An initial assessment of the assay was carried out using
105 samples that had been previously genotyped
with the commercial α-Globin StripAssay (ViennaLab
Diagnostics, Austria). These 105 samples included 70
samples that had deletions or duplications of one or
more of the α-globin genes. Samples with mutations of
Fig. 3 Normalized ratios of -dF/dT peak heights for different copy
numbers of the HBA1 and HBA2 genes. The horizontal bars indicate
the mean ratio and the vertical bars indicate the range from the
minimum to maximum ratio observed for each gene copy number.
The data was normalized with the equation: Normalized ratio = (RWT
Control/TWT Control)/(RSample/TSample), where R and T is reference gene
and target gene peak heights, respectively
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Fig. 4 (See legend on next page.)
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the HBA2 stop codon and UTR were also included to
ensure that they did not interfere with the assay
performance.
GRACE-PCR correctly identified the 70 samples
shown by the α-globin StripAssay to have deletions or
duplications of the α-globin genes (Table 2). Mutations
of the stop codon or UTR did not affect the copy num-
ber result, however, the -(α)20.5 deletion (Fig. 1) was de-
tected as a deletion of the HBA2 gene only. This was
because the -(α)20.5 deletion removes all of the HBA2
gene and the 5′ end of the HBA1 gene, but does not ex-
tend to the primer target at the 3′ end of the HBA1
gene. The performance of the GRACE-PCR assay was
further validated by the analysis of an additional 62
samples prior to genotyping by the α-globin StripAssay.
GRACE-PCR detected α-globin gene deletions in 38 of
these samples, all of which were subsequently confirmed
by genotyping (Table 2). Additionally, 143 samples were
analysed using alternative primers (Additional file 1:
Table S2) and no allele drop out was observed.
In total 108 of the samples were identified by the α-
globin StripAssay as having a deletion or duplication of
the α-globin genes. GRACE-PCR returned abnormal α-
globin gene copy numbers for all 108 positive samples
and did not generate any false positives (Table 2). This
equates to a sensitivity of 100.0 % (95 % confidence
interval 96.6-100.0 %) and a specificity of 100.0 % (95 %
confidence interval 93.9-100.0 %).
(See figure on previous page.)
Fig. 4 Normalization of GRACE-PCR assay to determine gene copy numbers. Raw melting curves show three distinct steps corresponding to the
melting of the CLCN7, HBA1 and HBA2 gene products generated during the GRACE-PCR Screening Test (a). Setting the normalization regions N1
and N2 (dark grey bars) in the HRM analysis software allowed the gene copy number ratio for CLCN7:HBA1 to be determined (b). Re-setting the
normalization regions to N3 and N4 (light grey bars) allowed the determination of the gene copy number ratio HBA1:HBA2 (c). The copy number
for CLCN7 is assumed to be two, which allows the number of HBA1 copies to be calculated, which in turn allows the determination of the
number of HBA2 copies
Table 2 Genotypes of samples used in the development and validation of the alpha globin gene ratio analysis copy enumeration
PCR assay (GRACE-PCR)
α-Globin StripAssay GRACE-PCR Screening Test
Genotype Strip Assay (n) PCR 1 (n) PCR 2 (n) CLCN7:HBA1 Ratio HBA1:HBA2 Ratio HBA1 Copies HBA2 Copies
1. αα/αα (wild type) 54 30 24 1:1 1:1 2 2
2. αα/-α3.7 48 29 19 1:1 2:1 2 (a) 1
3. -α3.7/-α3.7 36 20 16 1:1 1:0 2 (a) 0
4. αα/-α4.2 2 2 0 1:1 2:1 2 1
5. -α4.2/-α4.2 1 1 0 1:1 1:0 2 0
6. -α3.7/-α4.2 3 3 0 1:1 1:0 2 (a) 0
7. -α3.7/–SEA 6 3 3 2:1 1:0 1 (a) 0
8. αα/–Med 2 2 0 2:1 1:1 1 1
9. αα/–Fil 2 2 0 2:1 1:1 1 1
10. -(α)20.5 1 1 0 1:1 2:1 2 (b) 1
11. αα/αααanti3.7 2 2 0 1:1 2:3 2 3
12. -α3.7/αIcariaα (c) 1 1 0 1:1 2:1 2 (a) 1
13. αα/αpoly-A1α (c) 2 2 0 1:1 1:1 2 2
14. αα/αpoly-A2α (c) 1 1 0 1:1 1:1 2 2
15. -α3.7/αpolyA-1α (c) 4 4 0 1:1 2:1 2 (a) 1
16. αα/αConstant Springα (c) 1 1 0 1:1 1:1 2 2
17. αConstant Springα/αConstant Springα (c) 1 1 0 1:1 1:1 2 2
Total number of samples 167 105 62
The GRACE-PCR assay was assessed using samples with previously determined (PCR1) and unknown (PCR 2) genotypes. GRACE-PCR was able to detect all 108
samples identified by the commercial α-globin StripAssay as having α-globin gene rearrangements (genotypes 2 to12)
(a) Due to the positioning of primers at the 3′ ends of the α-globin genes, the hybrid -α3.7 gene is counted as an HBA1 gene in this assay
(b) The -(α)20.5 deletion does not extend to the 3′ end on the HBA1 gene targeted by the GRACE-PCR screening test primers, consequently only the deletion of the
HBA2 gene is detected
(c) Samples with point mutations (genotypes 12 to 17) were included to ensure that these point mutations did not affect the gene-copy number determination of
the GRACE-PCR assay
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Discussion
Conventional Gap-PCR and reverse hybridization assays
are commonly used methods to detect α-globin gene de-
letions [5–9]. These techniques are reliable and allow
identification of the specific targeted gene rearrange-
ments. However, Gap-PCR is not ideal for high volume
testing in a clinical laboratory, since it is relatively time
consuming and labour intensive. PCR protocols for Gap-
PCR require a long extension step in order to generate
fairly large amplicons; consequently cycling is slow and
typically takes approximately 3 h. The subsequent detec-
tion by agarose gel electrophoresis involves considerable
hands on time, adding around another 2 h to the ana-
lysis. In common with Gap-PCR, reverse hybridization
assays are open tube techniques that take several hours
to complete. Therefore, a stepwise clinical laboratory in-
vestigation incorporating a rapid screening step of α-
globin gene deletions has been suggested to be a more
efficient approach [26]. In our proposed workflow here,
all samples are first screened by the rapid and inexpen-
sive GRACE-PCR assay, and then all those identified
with a variant copy number are analysed further with a
different method that can identify the specific genotype.
The initial step in our workflow has the additional ad-
vantage that it can detect novel rearrangements not
identified by other assays, for example Gap-PCR.
Fragment analysis by capillary electrophoresis have
also been used to determine α-globin gene copy num-
bers [26–29]. These assays make use of the eight base
length differences between the HBA1 and HBA2 genes.
One limitation of these assays is that due to rearrange-
ments of the α-globin genes, such as the African α2
Polymorphism or the α12 allele, this difference in length
between the HBA1 and HBA2 genes can be absent [30–
32]. Indeed, these polymorphisms are reported to be
very common, with the African α2 Polymorphism reach-
ing a frequency of up to 12 % in some African popula-
tions [30]. In contrast, GRACE-PCR is not affected by
these gene rearrangements and it does not require the
use of a capillary electrophoresis based genetic analyser
making it a more universally applicable and faster
screening method.
In common with most PCR based techniques,
GRACE-PCR could potentially yield incorrect results
due to a SNP within a priming site inhibiting primer an-
nealing and therefore causing allele dropout. The 5′-end
of the reverse primer for HBA2 coincided with the stop
codon and consequently, there was a risk that mutations
of this codon might result in allele dropout. This was
tested by including samples from individuals carrying a
mutation in the stop codon, Hb Constant Spring
(HBA2:c.427T > C) and Hb Icaria (HBA2:c.427T > A), in
the assay validation. Our results showed that the assay
design was robust and the presence of the mutations of
the HBA2 stop codon did not affect the results (Table 2,
Genotypes 12, 16 and 17).
Some other low frequency SNPs have also been de-
scribed within the GRACE-PCR priming sites, the most
frequent of which (rs2261869) has a minor allele fre-
quency (MAF) of T = 0.0016 [33]. Thus, the possibility
of allele dropout needs be considered if an abnormal
GRACE-PCR result is obtained that cannot be con-
firmed by other methods. One possibility for checking
the original GRACE-PCR screening result is the use of
alternative primers for HBA2 and CLCN7 (Additional
file 1: Table S1) before proceeding to more complex tests
such as MLPA. In the current study all results of the
‘original’ and ‘alternate’ GRACE-PCRs were consistent
with the genotype from the StripAssay indicating that
no allele dropout had occured, suggesting that such
events should be rare.
We also considered the impact that point mutations
might have on the performance of GRACE-PCR. Point
mutations may alter the melt curve shapes, but would
have a negligible impact on total fluorescence, which is
dependent on the amplicon amount produced. Conse-
quently, point mutations are not expected to have a sig-
nificant impact on copy number determination, since
GRACE-PCR interpretation is dependent on the fall in
fluorescence as each amplicon melts. Indeed, inclusion
of samples with the αPoly A1 (HBA2:c.*92A >G) and αPoly A2
(HBA2:c.*94A > G) mutations in the method validation
confirmed that point mutations within the amplicons did
not affect the result interpretation (Table 2, Genotypes
13 to 15).
Other melt curve based methods have been previously
described for the detection of α-globin gene deletions.
Most of these are modified Gap-PCR assays that use
melting curve analysis as means of detection, thus
eliminating the need for agarose gel electrophoresis
[13, 18, 19, 34]. This makes them more convenient
than conventional Gap-PCR, but they have only been
developed for a limited set of deletions such as –SEA
and –THAI [19]. A melt curve method that compares
ratios of HBA1 and HBA2 gene PCR products has
also been described, but this method did not include
a reference gene and thus, required additional tubes
to detect certain genotypes [20].
The simplicity of quantitative PCR (qPCR) makes it
an attractive technology for copy number determin-
ation and methods for the α-globin genes have pre-
viously been described [14–17]. However, current
qPCRs either amplify the reference gene and each tar-
get gene in separate tubes [14, 17], or require the use
of expensive probes [15, 16]. Thus, such assays are
less convenient than the GRACE-PCR screening test,
which can be performed in a single tube without the
need for probes.
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In common with GRACE-PCR, both fragment analysis
by capillary electrophoresis and qPCR quantify the α-
globin genes relative to a reference gene that is assumed
to have a copy number of two. The current GRACE-PCR
assay used the well characterized CLCN7 gene for refer-
ence [14, 25, 35]. This gene is well suited for this applica-
tion because it has no pseudo-genes [14] and mutations
lead to autosomal dominant osteopetrosis, an uncommon
sclerosing bone disorder [35]. Consequently, individuals
without obvious bone abnormalities are expected to have
two intact copies of the gene. There is a common SNP
(rs2744995, MAF G = 0.3808) at the ultimate 5′ base of
the Screening Test CLCN7 gene reverse primer. Due to its
location at the 5′ end of the primer this SNP would not
be expected to affect the assay results. Indeed, CLCN7
copy numbers were identical when alternative primers
were used (Additional file 1: Table S2). No information
was available on bone abnormalities for the archived ma-
terial used in the current study, but the genotyping data
indicated that all subjects included in the study had two
copies of the CLCN7 gene and neither rs2744995 nor any
other SNPs that may have been present affected the re-
sults (Table 2). Additionally, in most cases copy number
changes or mispriming of the CLCN7 reference gene
would result in an improbable HBA1 copy number
highlighting samples for further investigation.
A limitation of methods that detect gene deletions or
duplications by copy number determination is that the
presence of deletions or duplications is inferred from the
total number of genes, rather than detected directly.
When an individual co-inherits both a deletion and du-
plication of a gene, the total number of genes does not
change and consequently such cases would appear nor-
mal. For example, the genotype -α3.7/αααanti3.7 has the
same number of α-globin genes as αα/αα and thus these
genotypes cannot be distinguished by copy number. This
limitation applies equally to GRACE-PCR, qPCR, capil-
lary electrophoresis fragment analysis and to MLPA.
Such combinations would be rare and would not affect
the phenotype of the individual carrying the mutations,
but they may be of clinical interest in some situations,
for example pre-marital genetic counselling.
Copy number based assays do not provide the identity
of the specific deletions/duplications detected. However,
the GRACE-PCR assay does differentiate between cases
with two alleles carrying α+ deletions (-α/-α) from cases
with a single αo deletion (αα/–). This clinically import-
ant distinction can be made because the test uses targets
at the 3′ end of each α-globin gene. The advantage of
this approach is that the -α3.7 hybrid allele types as an
HBA2 gene deletion, thus allowing compound heterozy-
gotes -α3.7/-α4.2 to be distinguished from a single large
αo deletion (αα/–). Assays that utilize targets 5′ of the
α-globin genes cannot make this distinction.
Finally, assays based on DHPLC have been described to
detect the common -α3.7, -α4.2 and –SEA deletions [12, 13].
DHPLC requires a specialized chromatography system for
detection and the post amplification processing takes
around 10 min for each sample. The GRACE-PCR assay
has a detection step that is far more rapid, taking around
10 min for a batch of 72 samples. Furthermore, with the
use of a plate based PCR system GRACE-PCR batch sizes
could be increased up to 384 samples without increasing
the post amplification processing time.
Conclusion
The GRACE-PCR test described here is a simple and ro-
bust method for simultaneous copy number assignment
of both the HBA1 and HBA2 genes. This method is well
suited for rapid initial screening of a large number of
samples since: (1) unlike Gap-PCR, DHPLC and capil-
lary electrophoresis based methods it does not require
extensive post-amplification processing of samples (i.e.
electrophoresis or chromatography); (2) in contrast to
fragment analysis by capillary electrophoresis-based as-
says it does not require the use of a capillary electro-
phoresis based genetic analyser and is not affected by
the common African α2 polymorphism; (3) in this closed
tube assay the risk of amplicon contamination is negli-
gible; and (4) the data analysis is very simple and allows
instant visual identification of any samples in a batch
with abnormal α-globin gene copy numbers.
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